Informed Consent in Clinical Trials: Key Issues and ICH Guidelines
This paper examines the informed consent process in clinical research, tracing its origins from early 20th-century abuses to the foundational protections established by the Declaration of Helsinki in 1964. Drawing on a review of relevant literature, the paper identifies key issues and concerns in obtaining informed consent from study participants, including protecting subject welfare, preventing coercion, ensuring voluntary participation, and providing information in subjects' native languages. These issues are analyzed in relation to Section 4.8 of the International Congress of Harmonization's "Guideline for Good Clinical Practice E6(R1)," which sets the controlling standard for informed consent in modern clinical trials.
- Introduction and Background: Historical context and paper's research purpose
- Defining Informed Consent: Legal definition and Declaration of Helsinki origins
- ICH Guidelines and Subject Autonomy: ICH Section 4.8 autonomy and consent requirements
- Preventing Coercion and Ensuring Comprehension: Anti-coercion rules, language access, and timing
- Conclusion: Summary of key informed consent obligations
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Anchors the discussion in a specific regulatory framework — Section 4.8 of the ICH Good Clinical Practice guideline — giving the analysis a clear, authoritative reference point.
- Integrates direct quotations from both legal and regulatory sources (Black's Law Dictionary, the ICH guideline, Saks and Golshan) to substantiate each claim without over-relying on paraphrase.
- Maintains a logical progression from definition, to historical foundation, to current regulatory requirements, to ethical safeguards, making the argument easy to follow.
Key academic technique demonstrated
The paper demonstrates effective use of regulatory and legal citation alongside scholarly literature. By placing the ICH guideline text in direct dialogue with peer-reviewed commentary (Bloswick & Skowron; Saks & Golshan), the author shows how regulatory language is interpreted and applied in practice — a technique common in health law, bioethics, and clinical research writing.
Structure breakdown
The paper opens with historical context and a clear statement of purpose, then moves through a definition of informed consent, an analysis of the ICH framework's autonomy provisions, and a discussion of anti-coercion and language-access requirements. The conclusion synthesizes the key obligations identified in the body. The structure is tightly focused for a short literature-review paper, with each paragraph advancing a distinct element of the informed consent framework.
Introduction and Background
Following a number of high-profile abuses of patients in experiments during the early 20th century, the need for a formal informed consent process became apparent. To determine the current state of affairs with this process, this paper reviews the relevant literature to explain the key issues and concerns involved in obtaining informed consent from study subjects, and how this process reflects the code of conduct set forth in Section 4.8 of the International Congress of Harmonization (ICH) Guideline for Good Clinical Practice E6(R1). A summary of the research and important findings concerning these key issues and concerns is presented in the conclusion.
Defining Informed Consent
The straightforward definition provided by Black's Law Dictionary states that informed consent is "a person's agreement to allow something to happen that is based on a full disclosure of facts needed to make the decision intelligently" (1990, p. 779). In 1964, the initial guideline for conducting clinical trials and for the protection of human subjects was published in the Declaration of Helsinki, which stipulated the fundamental requirement for patient protection and the centrality of human subjects' welfare above all other considerations in the conduct of clinical research (Bloswick & Skowron, 2015). In addition, the Declaration of Helsinki established the first provisions for obtaining formal informed consent from human subjects prior to their participation in clinical trials (Bloswick & Skowron, 2015).
ICH Guidelines and Subject Autonomy
According to Section 4.8 of the ICH's Guideline for Good Clinical Practice, the autonomy, dignity, and right to self-determination of human subjects participating in clinical trials are of paramount importance, and all relevant protocols and controlling legislation for obtaining informed consent must be followed. Moreover, informed consent provisions must be rigorously updated to ensure that all human subjects are provided with the most current guidance concerning the implications of their participation in a clinical trial (Guideline for Good Clinical Practice, 1996). This requirement is consistent with the guidance provided by Saks and Golshan (2013), who advise: "By speaking of 'an' informed consent, we do not mean to imply that this is something done only at the beginning of the process. In a 'process view' of an informed consent, an informed consent unfolds over time" (p. 2).
The World Health Organization and international regulatory bodies similarly emphasize that consent is an ongoing relationship between investigator and subject, not a one-time administrative formality. This dynamic understanding of consent reflects the ethical principle that participants must remain informed as new information about a trial emerges throughout the course of the study.
Conclusion
The research showed that, as the term implies, informed consent means providing human subjects with all of the information they need to make a decision concerning their participation in clinical trials. Some of the key issues and concerns involved in the informed consent process include placing the welfare of human subjects above all other considerations, ensuring that subjects are not subjected to undue pressure, making clear that their participation is voluntary and can be terminated without repercussions, and ensuring that the information provided to human subjects is in their native language with sufficient time allowed for them to reach a truly informed decision. These obligations, as codified in the Good Clinical Practice framework, represent the ethical foundation on which modern clinical research is conducted.
References
Black's law dictionary. (1990). St. Paul, MN: West Publishing Co.
Bloswick, A., & Skowron, H. A. (2015, Spring). Informed consent documentation in pharmaceutical industry-sponsored clinical trials. Ethics & Medicine, 31(1), 51–55.
Guideline for good clinical practice E6(R1). (1996, June 10). International Congress of Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Retrieved from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
Jhanwar, V., & Bishnoi, R. (2010, January–June). Comprehensibility of translated informed consent documents used in clinical research in psychiatry. Indian Journal of Psychological Medicine, 32(11), 7.
Saks, E. R., & Golshan, S. (2013). Informed consent to psychoanalysis: The law, the theory, and the data. New York: Fordham University Press.
Create your account
Always verify citation format against your institution’s current style guide requirements.